EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic dysregulation in MASLD-associated HCC: diagnostic biomarkers and therapeutic opportunities

Yu Geng, Lanqing Liu, Yongping Sun, Lijuan Guo, Yuanjing Wu, Zhen Jia

Frontiers in Medicine · 04.11.2025 · 12

DOI: 10.3389/fmed.2025.1705723 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Medicine, online erschienen am 04.11.2025. Verfasst von Yu Geng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Department, Binhai County People's Hospital, Yancheng, Jiangsu, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), has become the most common chronic liver disease globally, with its incidence rising annually. MASLD is closely linked to metabolic syndrome and can progress from simple steatosis to more severe stages, including non-alcoholic steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), affecting 13%–38.2% of cases. Notably, in 40%–50% of patients, this progression occurs without cirrhosis. The dysregulation of glucose and lipid metabolism is a fundamental pathological mechanism in MASLD and its transition to HCC. Key factors include insulin resistance, increased gluconeogenesis, impaired β-oxidation, oxidative stress, and chronic inflammation, all of which contribute to a tumor-promoting hepatic microenvironment. This review provides a comprehensive analysis of the latest research on MASLD-related HCC, emphasizing disturbances in glucose metabolism (such as disrupted hepatic insulin signaling, key enzymes like G6Pase and PK, and miRNAs such as miR-22-3p that induce Warburg effects), lipid imbalances (for example, upregulation of FASN/ACC and downregulation of PPARα targets like CPT1A), and the crosstalk between various pathways (including mTORC1, AMPK/ACC, FXR, and NF-κB/JNK). It also explores metabolic regulators such as DKK3, FGF21, and O-GlcNAcylation, and examines the role of the gut microbiota in modulating short-chain fatty acids, bile acids, and NLRP3 inflammasome activation in disease progression. By integrating the latest advancements in basic and clinical research, this article presents a solid theoretical framework for early diagnosis, risk assessment, biomarker development, and precision therapies. It also highlights promising therapeutic targets, including PPARα agonists, mTOR inhibitors, FGF21 analogs, and microbiota interventions, while proposing future directions in multi-omics and personalized treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

HCCMASLDgut microbiotametabolic dysregulationtherapeutic targets

Autor:innen und Institutionen

  • Interventional Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
  • Department of Acupuncture and Massage, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu, China.
  • Neonatal Medical Center, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Gynaecology and Obstetrics, Binhai County People's Hospital, Yancheng, Jiangsu, China.
  • Department of Laboratory, Haidong Second People's Hospital, Haidong, Qinghai, China.

Zitieren

APA

Geng, Y., Liu, L., Sun, Y., Guo, L., Wu, Y., & Jia, Z. (2025). Metabolic dysregulation in MASLD-associated HCC: diagnostic biomarkers and therapeutic opportunities. Frontiers in Medicine, 12. https://doi.org/10.3389/fmed.2025.1705723

Vancouver

Geng Y, Liu L, Sun Y, Guo L, Wu Y, Jia Z. Metabolic dysregulation in MASLD-associated HCC: diagnostic biomarkers and therapeutic opportunities. Frontiers in Medicine. 2025;12. doi:10.3389/fmed.2025.1705723

BibTeX
@article{Geng2025,
  author = {Geng, Yu and Liu, Lanqing and Sun, Yongping and Guo, Lijuan and Wu, Yuanjing and Jia, Zhen},
  title = {Metabolic dysregulation in MASLD-associated HCC: diagnostic biomarkers and therapeutic opportunities},
  journal = {Frontiers in Medicine},
  year = {2025},
  volume = {12},
  doi = {10.3389/fmed.2025.1705723}
}
Kostenlos starten →